The demand for sepsis diagnostic products is expected to grow mainly due to factors such as the increasing public-private funding for sepsis diagnostic research activities, the growing burden of infectious diseases, the rising number of sepsis incidences, and growing government initiatives for creating sepsis awareness.
The global spread of covid-19 and the emerging cases of sepsis among covid-19 patients are likely to increase the demand for rapid diagnosis, accelerating the utilization of instruments, reagents, & assay kits for detection of sepsis. Lockdowns resulting from the pandemic caused people to delay undergoing health checkups, affecting the number of tests performed and reagent sales.
đđđ đđšđ«đ đđ§đŹđąđ đĄđđŹ, đđ«đđ đđđ @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=92673155
The current COVID-19 pandemic has highlighted the risk faced by older adults, who are more susceptible to complications, including acute respiratory distress syndrome, usually due to pneumonia, which increases the risk of developing sepsis. Thus, increasing the need for early diagnosis of sepsis among patients with covid-19 infections.
The most common hospital-acquired infections (HAIs) are urinary tract infections, pneumonia, and sepsis. HAIs can lead to sepsis in immunocompromised patients, geriatric patients, and patients suffering from chronic illnesses. In the US, the incidence of sepsis among hospitalized patients is rising by 8.7% per year.
The cost of molecular diagnostic tests is between USD 300 and USD 3,000, which is very high compared to the cost of blood culture tests, priced as low as ~USD 28â35. Companies focus on developing automated diagnostic devices based on advanced technologies, such as molecular diagnostics.
For More Info, Speak To Our Expert @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=92673155
Sepsis is a very difficult condition to diagnose and the risk of mortality increases by 7.6% with a delay of even 1 minute in antibiotic administration in septic shock patients with hypertension.
Many sepsis diagnostic manufacturers are expanding their product offering in point of care technology rapidly detecting the sepsis, reducing the overall turnaround time of diagnosis. . The BACTEC Plus, BacT/Alert, and BACTEC FX blood culturing instruments manufactured by BD Company (US) is an automated microbial detection system offering a rapid diagnosis of sepsis in the turnaround time of three hours.
Sepsis is a life-threatening condition that needs to be diagnosed and treated at the earliest with the help of skilled healthcare professionals. The shortage of skilled professionals is a major concern worldwide; only 50% of patients with severe sepsis transported by the EMS system have a paramedic.
The sepsis diagnostics market, by technology, the market is segmented into blood culture, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers.
